We appreciate Dr Geller's comments on the complexities of prescription opioid pharmacology and additional factors of consideration in the safety and abuse of these medications. We believe he has a valid point in noting that the DEA schedules concern abuse potential and this only approximates to potency. However, most opioid-dosing tables and calculators consider oxycodone to be 1.5 times the potency of hydrocodone.1 Our choice of categorization by DEA schedule is consistent with the terminology used by practicing physicians, in current and proposed state and federal regulations,2,3 and in clinical guidelines.4 The specific medications categorized as schedule II short acting, schedule II long acting, and non–schedule II are listed in a table in our prior article.5
Braden JB, Sullivan MD. Correcting Several Oversimplifications of Chronic Opioid Therapy—Reply. Arch Intern Med. 2011;171(6):597–598. doi:10.1001/archinternmed.2011.85
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.